- Home
- ULCC vs IOVA Comparison
ULCC vs IOVA Comparison
Compare ULCC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- IOVA
- Stock Information
- Founded
- ULCC 1994
- IOVA 2007
- Country
- ULCC United States
- IOVA United States
- Employees
- ULCC N/A
- IOVA N/A
- Industry
- ULCC Air Freight/Delivery Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ULCC Consumer Discretionary
- IOVA Health Care
- Exchange
- ULCC Nasdaq
- IOVA Nasdaq
- Market Cap
- ULCC 719.5M
- IOVA 771.4M
- IPO Year
- ULCC 2021
- IOVA N/A
- Fundamental
- Price
- ULCC $4.16
- IOVA $2.21
- Analyst Decision
- ULCC Hold
- IOVA Buy
- Analyst Count
- ULCC 11
- IOVA 10
- Target Price
- ULCC $5.22
- IOVA $12.22
- AVG Volume (30 Days)
- ULCC 3.6M
- IOVA 12.5M
- Earning Date
- ULCC 08-07-2025
- IOVA 08-07-2025
- Dividend Yield
- ULCC N/A
- IOVA N/A
- EPS Growth
- ULCC N/A
- IOVA N/A
- EPS
- ULCC 0.30
- IOVA N/A
- Revenue
- ULCC $3,822,000,000.00
- IOVA $212,679,000.00
- Revenue This Year
- ULCC $4.64
- IOVA $86.62
- Revenue Next Year
- ULCC $12.84
- IOVA $69.95
- P/E Ratio
- ULCC $14.03
- IOVA N/A
- Revenue Growth
- ULCC 5.99
- IOVA 11070.12
- 52 Week Low
- ULCC $2.79
- IOVA $1.64
- 52 Week High
- ULCC $10.26
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- ULCC 57.35
- IOVA 53.22
- Support Level
- ULCC $4.03
- IOVA $1.70
- Resistance Level
- ULCC $4.22
- IOVA $2.15
- Average True Range (ATR)
- ULCC 0.22
- IOVA 0.13
- MACD
- ULCC 0.04
- IOVA 0.04
- Stochastic Oscillator
- ULCC 61.46
- IOVA 71.57
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.